Variant serum albumin with improved half-life and other properties
US10711050B2 · kind B2 · utility
3Cited by
83References
33Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 25, 2018 |
| Grant date | Jul 14, 2020 |
| Priority date | — |
| Expiry date | May 25, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/31
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides methods and materials for making and using variant serum albumin amino acid sequences which exhibit improved properties compared to wild type serum albumin sequences. The invention further provides methods and materials for making and using fusion proteins in which the variant serum albumin amino acid sequences are fused to a therapeutic or diagnostic agent, such as a therapeutic protein, or a functional fragment or variant thereof that maintains activity, and exhibits improved properties.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.